A Phase 2 interventional study of MAR in Alzheimer Disease, sponsored by Noah Pharmaceuticals, Inc.. Completed at 16 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Noah Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 months from Screening of the first patient until the last follow-up of the last patients.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's enrollment of 121 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →This is the only study on the registry with Noah Pharmaceuticals, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients may participate if they meet 1 of the following criteria:
Note: Patients with persistent menses due to hormonal therapy may participate if a urine pregnancy test (UPT) at the Screening Visit is negative and they agree to continued testing at every study visit.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MAR Active 0.6 g, Tablet, once-daily, 180 days
Drug: MAR
MAR Placebo 0.6 g, Tablet, once-daily, 180 days
Drug: MAR
Once-daily tablet
Clinical Dementia Rating - Global Score
CDR - Global Score: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The CDR scale is a widely used dementia staging instrument that produces a global score. This study will use global score for estimation, comparisons and analysis. The global score ranges from 0 to 3. The sites are instructed to use a standardized online calculator for scoring. This resulting calculation reflects the following scoring 0 = normal, no cognitive impairment; 0.5 = very mild dementia, minimal impairment in one domain; 1 = mild dementia, noticeable impairment in one or more domains; 2 = moderate dementia, significant impairment in multiple domains; 3 = severe dementia, major impairment in multiple domains.
Time frame: Day 210
Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score
CDR - SB: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The CDR scale is a widely used dementia staging instrument that produces a summated score (sum of boxes score). This study will use the summated score, comparisons and analysis. The "Sum of boxes" scoring methodology sums the score for each of the 6 domains and provides a value ranging from 0 to 18 that can change in of 0.5 or greater. Higher scores indicate greater disease severity. A positive change from baseline indicates clinical decline. Score Range from 0 to 18. Response choices are 0 = normal; 0.5 to 2.5 = questionable impairment; 3.0 to 4.0 = very mild dementia; 4.5 to 9.0 = mild dementia; 9.5 to 15.5 = moderate dementia; 16.0 to 18.0 = severe dementia.
Time frame: Day 210
Mini-Mental Scale Evaluation, 2nd Edition (MMSE-2) Score
MMSE-2: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The MMSE-2 is a widely used test of cognitive function among the elderly. The Standard Version consists of a 30-point questionnaire that includes tests of orientation, attention, memory, language, and visual-spatial skills. Score Range from 0 to 30. Response choices are 30 = normal; 26 to 29 = mild cognitive impairment; 21 to 25 = early stage dementia or mild cognitive impairment; 11 to 20 = middle stage dementia or moderate cognitive impairment; 0 to 10 = late stage dementia or severe cognitive impairment.
Time frame: Day 210
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-COG)
ADAS-COG: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The ADAS-COG is used to assess cognitive symptoms of dementia. It consists of 7 performance items and 4 clinician-rated items assessing memory, orientation, language and praxis. Score Range from 0 to 70. Response choices are 0 to 10 = minimal to no cognitive impairment; 11 to 20 = mild cognitive impairment; 21 to 30 = moderate cognitive impairment; 31 to 70 = severe cognitive impairment.
Time frame: Day 210
Alzheimer's Disease Cooperative Study-ADL scale (ADCS-ADL)
ADCS-ADL: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The ADCS-ADL is a comprehensive battery of ADL questions used to measure the functional capabilities of patients; each item is rated from the highest level of independent performance to complete loss. Score Range from 0 to 78. Response choices are 0 to 20 = severe impairment; 21 to 40 = moderate impairment; 41 to 60 = mild impairment; 61 to 78 = minimal impairment.
Time frame: Day 210
Clinical Global Impressions - Improvement (CGI-I)
CGI-I: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The Clinical Global Impressions-Improvement (CGI-I) scale will be assessed at all visits after Baseline. The Investigator (or designee) will answer the following question: "Compared to the patient's condition at Baseline. Score Range from 1 to 7. Response choices are: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change from Baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since Baseline".
Time frame: Day 210
Clinical Global Impressions - Severity (CGI-S)
CGI-S: To estimate the magnitude and variability of clinical response to a drug combination Tablet in patients with Alzheimer's disease (AD) after 180 days of treatment against Placebo Tablet. The Clinical Global Impressions-Severity (CGI-S) scale will be assessed at Baseline and all visits afterward. The Investigator (or designee) will answer the following question: "Considering your total clinical experience with AD, how ill is the patient at this time?" Score Range from 1 to 7. Response choices are 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
Time frame: Day 210
Clinical Dementia Rating - Global Score (Exploratory)
Change from Baseline in the Clinical Dementia Rating - Global Score after 210 days (Global Score ranges from 0 to 3; a lower score indicates no disease; a higher score indicates greater disease severity; 0 = normal, 3 = severe dementia)
Time frame: Day 210
Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score (Exploratory)
Change from Baseline in CDR-SB Score after 210 days (CDR-SB Score ranges from 0 to 18; a lower score indicates no disease; a higher score indicates greater disease severity; 0 = normal, 18 = severe dementia)
Time frame: Day 210
Mini-Mental Scale Evaluation, 2nd Edition (MMSE-2) Score (Exploratory)
Change from Baseline from MMSE-2 Score through 210 days (MMSE-2 Score ranges from 0 to 30; a lower score indicates severe dementia; a higher score indicates better cognitive function; 0 to 10 = late stage dementia or severe cognitive impairment, 30 = normal)
Time frame: Day 210
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-COG) (Exploratory)
Change from Baseline in ADAS-COG Score through 210 days (ADAS-COG Score ranges from 0 to 70; a lower score indicates better cognitive function; a higher score indicates greater dysfunction; 0 to 10 = minimal to no cognitive impairment, 31 to 70 = severe cognitive impairment)
Time frame: Day 210
Alzheimer's Disease Cooperative Study-ADL scale (ADCS-ADL) (Exploratory)
Change from Baseline in ADCS-ADL Score through 210 days (ADCS-ADL Score ranges from 0 to 78; a lower score indicates greater severity; a higher score indicates better functioning in daily activities; 0 to 20 = severe impairment, 61 to 78 = minimal impairment)
Time frame: Day 210
Clinical Global Impressions - Improvement (CGI-I) (Exploratory)
Change from Baseline in CGI-I Score through 210 days (CGI-I Score ranges from 1 to 7; a lower score indicates the patient has improved; a higher score indicates the patient is very much worse since Baseline; 1 = very much improved, 7 = very much worse since Baseline)
Time frame: Day 210
Clinical Global Impressions - Severity (CGI-S) (Exploratory)
Change from Baseline in CGI-S Score through 210 days (CGI-S Score ranges from 1 to 7; a lower score indicates the patient is less severely ill; a higher score indicates among the most extremely ill patients; 1 = normal, not at all ill, 7 = among the most extremely ill patients)
Time frame: Day 210
Treatment-emergent adverse events (TEAEs)
Incidence of TEAEs through Day 210
Time frame: Day 210
Serious Adverse Events (SAEs)
Incidence of SAEs from informed consent through Day 210
Time frame: Day 210
Adverse Events (AEs)
Incidence of AEs from informed consent through Day 210
Time frame: Day 210
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Nov 2025, 12 months.
Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 12 months is below that.
Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.